Jun-Qi Zhu

Jun-Qi Zhu

Auto-generated profile, based on publicly available information

Jun-Qi Zhu

Thorgene Co., Ltd, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Environmental Pollution
Verified
Journal Article
Closed access
JDJason Dexter
Jason Dexter
DDDariusz Dziga
Dariusz Dziga
JLJing Lv
Jing Lv
JZJunqi Zhu
Junqi Zhu
WSWojciech Strzałka
Wojciech Strzałka
Pengcheng FuPengcheng Fu
Pengcheng Fu

28 September 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
YLYu-Lin Lin
Yu-Lin Lin
JZJun-Qi Zhu
Jun-Qi Zhu
RMRuiqing Ma
Ruiqing Ma
WMWei Meng
Wei Meng
ZWZi-Yue Wang
Zi-Yue Wang
YLYan Li
Yan Li
Pseudomyxoma peritonei (PMP) is a rare malignant clinical syndrome with little known about the global mutation profile. In this study, whole-exome sequencing (WES) was performed in 49 appendiceal PMP to investigate mutation profiles and mutation signatures. A total of 4,020 somatic mutations were detected, with a median mutation number of 56 (1–402). Tumor mutation burden (TMB) was generally low (median 1.55 mutations/Mb, 0.12–11.26 mutations/Mb). Mutations were mainly enriched in the function of cancer-related axonogenesis, extracellular matrix–related processes, calcium signaling pathway, and cAMP signaling pathway. Mutations in FCGBP, RBFOX1, SPEG, RTK-RAS, PI3K-AKT, and focal adhesion pathways were associated with high-grade mucinous carcinoma peritonei. These findings revealed distinct mutation profile in appendiceal PMP. Ten mutation signatures were identified, dividing patients into mutation signature cluster (MSC) 1 (N = 28, 57.1%) and MSC 2 (N = 21, 42.9%) groups. MSC (P = 0.007) was one of the four independent factors associated with 3-year survival. TMB (P = 0.003) and microsatellite instability (P = 0.002) were independent factors associated with MSC 2 grouping. Taken together, our findings provided a broader view in the understanding of molecular pathologic mechanism in appendiceal PMP and may be critical to developing an individualized approach to appendiceal PMP treatment. Implications: This work describes exhaustive mutation profile of PMP based on WES data and derives ten mutation signatures, which divides patients into two clusters and serve as an independent prognostic factor associated with 3-year survival.

8 November 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SZShaowen Zhang
Shaowen Zhang
PDPing Dong
Ping Dong
ZPZongwei Pan
Zongwei Pan
QCQian Chen
Qian Chen
JZJunqi Zhu
Junqi Zhu
ZMZhangfan Mao
Zhangfan Mao

2 January 2024
Verified
Other
Open access
YLYu-Lin Lin
Yu-Lin Lin
JZJun-Qi Zhu
Jun-Qi Zhu
RMRuiqing Ma
Ruiqing Ma
WMWei Meng
Wei Meng
ZWZi-Yue Wang
Zi-Yue Wang
YLYan Li
Yan Li
The correlation between clinicopathological factors and two MSC groups

2 January 2024
Verified
Other
Open access
YLYu-Lin Lin
Yu-Lin Lin
JZJun-Qi Zhu
Jun-Qi Zhu
RMRuiqing Ma
Ruiqing Ma
WMWei Meng
Wei Meng
ZWZi-Yue Wang
Zi-Yue Wang
YLYan Li
Yan Li
Mutation characteristics of 49 PMP and site mutation information of the top 20 gene mutations

2 January 2024
Verified
Other
Open access
PDF file
YLYu-Lin Lin
Yu-Lin Lin
JZJun-Qi Zhu
Jun-Qi Zhu
RMRuiqing Ma
Ruiqing Ma
WMWei Meng
Wei Meng
ZWZi-Yue Wang
Zi-Yue Wang
YLYan Li
Yan Li
Driver genes derived from OncodriveCLUST and OncodirveFML. A: Five driver genes determined by OncodriveCLUST; B: Four driver genes determined by OncodirveFML.